rethinkTHC Search
Menu
Study breakdown

Cannabis may interact with blood thinners and antiplatelet drugs through liver enzyme competition

ReviewModerate evidence
The takeaway

A review of 665 screened articles identified potential interactions between cannabis and anticoagulants/antiplatelets, including THC increasing warfarin levels via CYP2C9 inhibition and CBD potentially reducing clopidogrel effectiveness via CYP2C19 inhibition.

Cardiologists, pharmacists, patients on blood thinners, and cannabis-using patients with cardiovascular conditions.

THC inhibits CYP2C9 (warfarin); CBD inhibits CYP2C19 (clopidogrel)

What the researchers found

Cannabis components can inhibit liver enzymes (CYP2C9, CYP2C19) and transporters involved in metabolizing blood thinners. Case reports showed cannabis inhibited warfarin metabolism, increasing INR and bleeding risk. CBD may reduce conversion of clopidogrel to its active form, potentially increasing stroke risk.

Why it matters

Patients using blood thinners for cardiac conditions, stroke prevention, or post-stent management are at high risk from drug interactions. With increasing medical and recreational cannabis use, clinicians need to be aware of these potential interactions.

The numbers in context

665 articles screened, 6 relevant publications identified. THC inhibits CYP2C9 (warfarin metabolism). CBD inhibits CYP2C19 (clopidogrel activation). Case reports documented increased INR with cannabis-warfarin co-use.

How the study worked

Review screening 665 articles from PubMed and EMBASE. Six relevant publications were identified: 4 case reports, 1 in vitro study, and 1 pharmacokinetic article.

What this study cannot tell us

Very limited direct evidence (only 6 relevant publications). Most data comes from case reports and in vitro studies. Clinical significance of these interactions in real-world dosing is not well established.

How to read the evidence

Moderate: plausible pharmacological mechanisms supported by case reports, but very limited clinical data.

When this study was published

Published in 2020 in Journal of Clinical Pharmacology.

The bigger picture

These interactions highlight a gap in patient counseling: patients on life-critical medications like warfarin or clopidogrel may not be asked about cannabis use, and cannabis users may not realize the risks of combining it with their prescribed medications.

Questions still open

  • Should patients on blood thinners receive routine counseling about cannabis interactions? How clinically significant are these interactions at typical cannabis doses? Should INR monitoring be increased in warfarin patients who use cannabis?

Common questions

Can I use cannabis while taking blood thinners?
This review identifies potential risks. THC may increase warfarin levels, raising bleeding risk, while CBD may reduce clopidogrel effectiveness. Patients on these medications should discuss cannabis use with their prescribing physician.
How strong is the evidence?
The evidence is limited to a few case reports and laboratory studies. The pharmacological mechanisms are plausible, but large clinical studies have not been done to determine how often these interactions cause actual problems.

Read the original research

A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents.

Journal of clinical pharmacology, 60(4), 432-438

Citation

Greger, Jessica; Bates, Vernice; Mechtler, Laszlo; Gengo, Fran. (2020). A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents.. Journal of clinical pharmacology, 60(4), 432-438. https://doi.org/10.1002/jcph.1557

Explore the wider topic